4888

繧ｹ繝�繝ｩ繝輔ぃ繝ｼ繝樊ｪ蠑丈ｼ夂､ｾ

ステラファーマ株式会社
Pharmaceutical
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.
← Companies
Price
¥357
Market Cap
¥12.2B
Ent. Value
¥9.7B
Net Cash
¥2.4B
Shares Out.
34.0M
P / E
—
EV / EBIT
—
P / Book
3.79×
P / NCAV
4.00×
Div. Yield
—
Financials
Metric FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥961M ¥269M ¥229M ¥100M
Gross Profit ¥846M ¥217M ¥207M ¥85M
SG&A ¥936M ¥978M ¥1.0B ¥827M
Operating Income ¥-90M ¥-760M ¥-807M ¥-742M
Non-Operating Income ¥12M ¥5M ¥41M ¥18M
Interest Income ¥1M ¥0M ¥0M ¥0M
Non-Operating Expenses ¥59M ¥5M ¥10M ¥40M
Interest Expense ¥4M ¥2M ¥3M ¥3M
Ordinary Income ¥-138M ¥-760M ¥-776M ¥-764M
Pre-tax Income ¥-138M ¥-761M ¥-776M ¥-764M
Income Taxes ¥3M ¥3M ¥3M ¥4M
Current Tax ¥3M ¥3M ¥3M ¥4M
Net Income (owners) ¥-141M ¥-764M ¥-779M ¥-768M
EBITDA ¥-56M ¥-725M ¥-772M ¥-708M
EPS ¥-4.22 ¥-24.66 ¥-26.97 ¥-27.34
Shares Outstanding 34.0M 31.2M 30.0M 28.7M
Shares Issued (total) 34.0M 31.2M 30.0M 28.7M